by: Parent Project Muscular DystrophyPTC Therapeutics joined PPMD for a community webinar on December 9, 2022 for a discussion regarding PTC’s history with the community and plans for the future, including activities to bring ataluren (Translarna) to US patients with nonsense mutations.
